Refractory bleeding from portal hypertensive gastropathy: A further novel role for thalidomide therapy?

European Journal of Gastroenterology and Hepatology

Volumn 18, Issue 5, 2006, Pages 545-548

  Karajeh, Mohammed A ^a   Hurlstone, David P ^a   Stephenson, Tim J ^a   Ray Chaudhuri, Dominic ^a   Gleeson, Dermot C ^a  

^a ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

Author keywords

Cholangiocarcinoma; Gastrointestinal bleeding; Portal hypertension; Portal hypertensive gastropathy; Thalidomide

Indexed keywords

GEMCITABINE; OMEPRAZOLE; PROPRANOLOL; SUCRALFATE; TERLIPRESSIN; THALIDOMIDE; TRANEXAMIC ACID;

ABSENCE OF SIDE EFFECTS; ADULT; ANAMNESIS; ARTICLE; BILE DUCT CARCINOMA; BLEEDING; BLOOD TRANSFUSION; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; GASTROSCOPY; HUMAN; HUMAN TISSUE; LABORATORY TEST; MALE; MAXIMUM PERMISSIBLE DOSE; MELENA; PORTAL HYPERTENSION; PORTAL VEIN OBSTRUCTION; PRIORITY JOURNAL; STOMACH BIOPSY; STOMACH DISEASE;

ANGIOGENESIS INHIBITORS; BIOPSY; ESOPHAGEAL AND GASTRIC VARICES; GASTROINTESTINAL HEMORRHAGE; HUMANS; MALE; MIDDLE AGED; PORTAL VEIN; PYLORIC ANTRUM; THALIDOMIDE; TREATMENT OUTCOME;

EID: 33744783401     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042737-200605000-00016     Document Type: Article

References (14)

1. Sarin SK, Sreenivas DV, Lahoti D, Saraya A. Factors influencing development of portal hypertensive gastropathy in patients with portal hypertension. Gastroenterology 1992; 102:994-999.
2. Burak KW, Lee SS, Beck PL. Portal hypertensive gastropathy and gastric antral vascular ectasia (GAVE) syndrome. Gut 2001; 49:866-872.
3. Payen JL, Cales P, Voigt JJ, Barge S, Pilette C, Dubuisson L, et al. Severe portal hypertensive gastropathy and antral vascular ectasia are distinct entities in patients with cirrhosis. Gastroenterology 1995; 108:138-144.
4. Munoz J, Albillos A, Perez-Paramo M, Rossi I, Alvarez-Mon M. Factors mediating the hemodynamic effects of tumor necrosis factor-alpha in portal hypertensive rats. Am J Physiol 1999; 276:G687-G693.
5. Ohta M, Tarnawski AS, Itani R, Pai R, Tomikawa M, Sugimachi K, Sarfeh IJ. Tumor necrosis factor alpha regulates nitric oxide synthase expression in portal hypertensive gastric mucosa of rats. Hepatology 1998; 27:906-913.
6. Lopez-Talavera JC, Merrill WW, Groszmann RJ. Tumor necrosis factor alpha: a major contributor to the hyperdynamic circulation in prehepatic portal-hypertensive rats. Gastroenterology 1995; 108:761-767.
7. Sampaio EP, Sarno EN, Galilly R, Cohn ZA, Kaplan G. Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. J Exp Med 1991; 173:699-703.
8. Lopez-Talavera JC, Cadelina G, Olchowski J, Merrill W, Groszmann RJ. Thalidomide inhibits tumor necrosis factor alpha, decreases nitric oxide synthesis, and ameliorates the hyperdynamic circulatory syndrome in portal-hypertensive rats. Hepatology 1996; 23:1616-1621.
9. Austin AS, Mahida YR, Clarke D, Ryder SD, Freeman JG. A pilot study to investigate the use of oxpentifylline (pentoxifylline) and thalidomide in portal hypertension secondary to alcoholic cirrhosis. Aliment Pharmacol Ther 2004; 19:79-88.
10. D'Amato RJ, Loughnan MS, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 1994; 91:4082-4085.
11. Lee RJ, Springer ML, Blanco-Bose WE, Shaw R, Urwell PC, Blau HM. VEGF gene delivery to myocardium: deleterious effects of unregulated expression. Circulation 2000; 102:898-901.
12. Bauditz J, Schachschal G, Wedel S, Lochs H. Thalidomide for treatment of severe intestinal bleeding. Gut 2004; 53:609-612.
13. Benckert C, Jonas S, Cramer T, Von Marschall Z, Schafer G, Peters M, et al. Transforming growth factor β1 stimulates vascular endothelial growth factor gene transcription in human cholangiocellular carcinoma cells. Cancer Res 2003; 63:1083-1092.
14. Khan SA, Davidson BR, Goldin R, Pereira SP, Rosenberg WM, Taylor-Robinson SD, et al. Guidelines for the diagnosis and treatment of cholangiocarcinoma: consensus document. Gut 2002; 51(suppl 6):1-9.